Hotspot vs Traditional Radiotherapy for Lung Cancer

This trial explores two types of radiation therapy for individuals with early-stage non-small cell lung cancer. It compares standard radiation treatment to a new method that targets the tumor with extra-high doses, known as "hot spots" (Stereotactic Body Radiation Therapy, or SBRT, with Hot Spots). The researchers aim to determine if this new method better controls the cancer, though it might also cause more side effects. Individuals diagnosed with early-stage non-small cell lung cancer who haven't received radiation to the chest area in the past six months might be suitable candidates. As a Phase 2 trial, this research focuses on measuring the treatment's effectiveness in an initial, smaller group of participants.

Research has shown that stereotactic body radiation therapy (SBRT) with hot spots can cause more side effects, particularly for tumors located in the center of the lung. Patients might experience more side effects compared to other treatments. However, SBRT is designed to deliver higher doses of radiation directly to the tumor, potentially improving control.

Past studies have demonstrated SBRT's effectiveness in controlling cancer in the treated area. For instance, one study found it controlled cancer in 92% of patients. Despite the risk of side effects, many patients tolerate the treatment well, achieving good results in managing early-stage non-small cell lung cancer.

Researchers are excited about using Hotspot Stereotactic Body Radiation Therapy (SBRT) for lung cancer because it targets the tumor with higher radiation doses in fewer sessions. Unlike traditional SBRT, this approach potentially maximizes tumor control while minimizing exposure to surrounding healthy tissues, reducing side effects. Most lung cancer treatments involve continuous radiation over several weeks, but Hotspot SBRT can deliver effective results in just 1-5 sessions over 1-11 days, offering a quicker and potentially more effective alternative.

This trial will compare two approaches to stereotactic body radiation therapy (SBRT) for lung cancer: hot spot SBRT and standard-of-care (SOC) SBRT. Research has shown that stereotactic ablative body radiotherapy (SABR), similar to SBRT, holds promise for treating early-stage non-small cell lung cancer (NSCLC). SABR uses focused radiation to precisely target tumors, helping to control their growth. Studies have found that SABR can offer results similar to surgery for patients unable to undergo an operation. Additionally, SABR can deliver a higher dose of radiation directly to the tumor, potentially improving its effectiveness. However, this could also increase side effects. While SABR has proven effective, researchers continue to study the use of higher doses to understand its benefits and risks.⁶⁷⁸⁹¹⁰